Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results for the Akt inhibitor MK-2206 in advanced gastric and gastroesophageal junction cancers have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Diffuse Gastric Adenocarcinoma
• Gastric Carcinoma
• Gastric Intestinal Type Adenocarcinoma
• Gastric Mixed Adenocarcinoma

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-08-04